NantHealth & NantOmics to Present Data on the Frequency of Non-Expressed Variants Tested by Standard NGS Panel at the America...
June 02 2018 - 4:23PM
Business Wire
Results to be presented during the tumor
biology session at the American Society of Clinical Oncology (ASCO)
2018 Annual Meeting
NantWorks, LLC today announced that its affiliate companies,
NantHealth, Inc., (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company and NantOmics, LLC,
the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, will present findings on how 17 percent of
next generation sequencing (NGS) 50 gene panel variants are not
expressed in RNA sequencing during the tumor biology session at the
American Society of Clinical Oncology (ASCO) 2018 Annual Meeting,
an event bringing together 30,000 oncology professionals from June
1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will
be exhibiting at booth #7147 during the event.
“By determining the frequency of non-expressed variants that
would be tested by a standard NGS panel, our data shows that the
identification of these genes can yield improved testing algorithms
and treatment strategies,” said Patrick Soon-Shiong, MD, founder of
NantWorks. “We’re excited to share this data and look forward to
further exploring how NGS can be used for target therapy in
oncology.”
Presentation Details
Seventeen percent of NGS 50 gene panel variants are not
expressed in RNAseq, Abstract #12118WHO:
NantHealth, LLC and NantOmics, LLCWHAT: Tumor Biology
SessionWHEN: June 4, 1:15-4:45 PM CSTWHERE: Hall A,
McCormick Place
Presentation Summary
This study analyzed the frequency of non-expressed variants that
would be tested by a standard NGS panel through retrospective
analysis of a database from a commercial DNA tumor: normal and
RNAseq platform. In the 992 samples that were identified with
paired DNA (WGS or WES) / RNAseq NGS, a total of 225,727 SNVs were
detected. Across 37 tumor types the range of expression was 57%
(melanoma) – 100% (uterine). In this analysis, 17 percent of
detected variants were not expressed in the RNA sequence. As a
result, the lack of RNA expression may contribute to less than
expected clinical benefit with molecularly targeted therapies.
Since the distribution is non-uniform, identification of these
genes can yield improved testing algorithms and treatment
strategies.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular diagnostic capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular diagnostics company to
pioneer an integrated approach to unearthing the genomic and
proteomic variances that initiate and drive cancer, by analyzing
both normal and tumor cells from the same patient and following
identified variances through from DNA to RNA to protein to drug.
NantOmics has a highly scalable cloud-based infrastructure capable
of storing and processing thousands of genomes a day, computing
genomic variances in near real-time, and correlating proteomic
pathway analysis with quantitative multi-plexed protein expression
analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please
visit www.nantomics.com and follow Dr. Soon-Shiong on
Twitter @DrPatSoonShiong.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180602005099/en/
NANTJen Hodsonjhodson@nantworks.comorNANTHenry C.
Jacksoncj@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024